







# D6.6 Video explaining new knowledge on transdiagnostic approach

#### PRISM 2 - GA 101034377 **Psychiatric Ratings using Intermediate Stratified Markers 2**

## WP6 Dissemination, communication, exploitation and training

Lead contributors	Ligia Bohn (ECNP) Hugh Marston (BI)
Other contributors	Juliane Dittrich (concentris research management gmbh)
	Martien Kas (RUG)
	Tom Parkhill, ECNP press officer

Due date	30 Nov 2024
Delivery date	27 Nov 2024
Deliverable type	OTHER
Dissemination level	PU

Description of Work	Version	Date
	V1	21 March 2024

### **Document History**

Version	Date	Description
V1.1	11 Oct. 2024	Draft script
V1.2	22 Oct. 2024	Final script
V1.3	12 Nov 2024	First version video
V1.3	18 Nov 2024	Comments to video company
V2.0	24 Nov 24	Second version video
V3.0	27 Nov 2024	Final version









GA 101034377 PRISM 2 - D6.6

#### **Publishable Summary**

As part of the dissemination activities of WP6, a video was produced explaining what the PRISM project is about and how PRISM 2 can contribute to the opening up of new therapeutic approaches.

The script of the video was written by a team consisting of the PRISM2 project coordinators and the ECNP communications team along with the ECNP press officer, Tom Parkhill. To enrich the quality of the video, unused footage (copyright free) from a Dutch documentary on precision psychiatry was included. The footage was provided free of charge by the producer of the documentary.

Once the main PRISM2 publication on the clinical study addressing the primary study objective has been accepted for publication, the PRISM2 video will be distributed to all PRISM2 partners and the IHI who then can distribute the video through all their own available channels. In addition, the video will be published on the PRISM2 website and the PRISM2-X account. It will then be sent to the entire ECNP database (more than 30,000 people from the scientific community, including policy makers, patient organisations, etc.). The video will also be published on the ECNP's YouTube channel, on the website (more than 95,000 visitors per year) and on the ECNP's social media channels, which gives additional visibility due to the many followers that ECNP has.

The link to the video is available on request. Please note that the video cannot be distributed at this stage (see above).

#### Acknowledgement

The PRISM 2 project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101034377. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Cohen Veterans Bioscience. The information reflects only the authors' views neither IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein.